Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants.

Postnatal Corticosteroids to Treat or Prevent Chronic Lung Disease in Preterm

Policy Statement—Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia

The purpose of this revised statement is to review current information on the use of postnatal glucocorticoids to prevent or treat bronchopulmonary dysplasia in the preterm infant and to make updated recommendations regarding their use. High-dose dexamethasone (0.5 mg/kg per day) does not seem to confer additional therapeutic benefit over lower doses and is not recommended. Evidence is insuffic...

Review: early postnatal corticosteroids reduce chronic lung disease in preterm infants, but increase complications.

Postnatal corticosteroids in preterm infants: systematic review of effects on mortality and motor function.

BACKGROUND Postnatal corticosteroid therapy has been proved in randomized controlled trials to reduce ventilator dependence and the rate of chronic lung disease in preterm infants with few serious short-term side effects. However, there are other consequences that might follow postnatal corticosteroid therapy that are more important, including mortality or cerebral palsy. OBJECTIVES To review...

Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review.

BACKGROUND Corticosteroids have been used widely after birth in preterm infants with respiratory failure; hydrocortisone may be preferable to other corticosteroids for this purpose. OBJECTIVES To determine if postnatal hydrocortisone is useful to prevent or treat bronchopulmonary dysplasia (BPD) in preterm infants. METHODS Randomised controlled trials (RCTs) of postnatal hydrocortisone ther...